FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2615103477> ?p ?o ?g. }

• W2615103477 endingPage "54721" @default.
• W2615103477 startingPage "54708" @default.
• W2615103477 abstract "// Luis León-Mateos 1, * , Helena Casas 2, * , Alicia Abalo 2, 3 , María Vieito 6 , Manuel Abreu 2, 3 , Urbano Anido 3 , Antonio Gómez-Tato 4 , Rafael López 2, 3, 5 , Miguel Abal 3 and Laura Muinelo-Romay 3 1 Axencia Galega de Coñecemento en Saúde (ACIS), SERGAS, Santiago de Compostela, Spain 2 Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), CIBERONC, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain 3 Translational Medical Oncology Group, Health Research Institute of Santiago (IDIS), CIBERONC, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain 4 School of Mathematics, University of Santiago de Compostela (Campus Vida), Santiago de Compostela, Spain 5 Roche-Chus Joint Unit for Precision Oncology, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain 6 Research Unit for Molecular Therapy of Cancer, CNS Tumors, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain * Co first-authors Correspondence to: Luis León-Mateos, email: Luis.Leon.Mateos@sergas.es Laura Muinelo-Romay, email: lmuirom@gmail.com Keywords: prostate cancer, circulating tumour cells (CTCs), prognostic markers, taxanes resistance Received: January 17, 2017      Accepted: May 02, 2017      Published: May 19, 2017 ABSTRACT Introduction: There is a critical need of new surrogate markers for improving the therapeutic selection and monitoring of metastatic prostate cancer patients. Nowadays clinical management of these patients is been driven by biochemical and clinical parameters without enough accuracy to allow a real personalized medicine. The present study was conducted to go insight the molecular profile of circulating tumor cells (CTCs) isolated from advanced metastatic castration-resistant prostate cancer (mCRPC) with the aim of identifying prognostic marker with potential utility for therapy selection and monitoring. Materials and Methods: CTCs isolation was carried out in peripheral blood samples from 29 mCRPC patients that undergo systemic chemotherapy based on taxanes (docetaxel/cabazitaxel) and 19 healthy controls using in parallel CellSearch and an alternative EpCAM-based immunoisolation followed by RT-qPCR analysis to characterize the CTC population. A panel of 17 genes related with prostate biology, hormone regulation, stem properties, tumor aggressiveness and taxanes responsiveness was analysed to identify an expression signature characterizing the CTCs. Results: Patients with ≥ 5 CTCs/7.5ml of peripheral blood at baseline and during the treatment showed lower progression free survival (PFS) and overall survival (OS). Changes of CTCs levels during the treatment were also associated with the patient’s outcome. These results confirmed previous data obtained using CellSearch in mCRPC. In addition, we found a CTC profile mainly characterized by the expression of relevant genes for the hormone dependent regulation of PCa such as AR and CYP19 together with genes strongly implicated in PCa progression and resistance development such as BIRC5 , TUB1A , GDF15 , RAB7 and SPINK1 . Our gene-expression profiling also permitted the identification of valuable prognostic biomarkers. Thus, high levels of AR, CYP19 and GDF15 were associated with poor PFS rates while AR, GDF15 and BIRC5 were also found as reliable predictors of OS. Besides, a logistic model using KLK3 and BIRC5 showed a high specificity and sensitivity compared to CellSearch to discriminate patients with a more aggressive evolution. Conclusions: The molecular characterization of CTCs from advanced mCRPC patients provided with a panel of specific biomarkers, including genes related to taxanes resistance, with a promising applicability as “liquid biopsy” for the management of these patients." @default.
• W2615103477 created "2017-05-26" @default.
• W2615103477 creator A5004217317 @default.
• W2615103477 creator A5016992044 @default.
• W2615103477 creator A5048840478 @default.
• W2615103477 creator A5052120847 @default.
• W2615103477 creator A5053521596 @default.
• W2615103477 creator A5060787732 @default.
• W2615103477 creator A5060971333 @default.
• W2615103477 creator A5077458179 @default.
• W2615103477 creator A5080643331 @default.
• W2615103477 creator A5084392897 @default.
• W2615103477 date "2017-05-19" @default.
• W2615103477 modified "2023-09-23" @default.
• W2615103477 title "Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients" @default.
• W2615103477 cites W1599161148 @default.
• W2615103477 cites W1661862144 @default.
• W2615103477 cites W1795246178 @default.
• W2615103477 cites W1844925317 @default.
• W2615103477 cites W1917588793 @default.
• W2615103477 cites W1964743637 @default.
• W2615103477 cites W1968083225 @default.
• W2615103477 cites W1997930286 @default.
• W2615103477 cites W2006352011 @default.
• W2615103477 cites W2017650826 @default.
• W2615103477 cites W2017881185 @default.
• W2615103477 cites W2017896209 @default.
• W2615103477 cites W2020579083 @default.
• W2615103477 cites W2023292784 @default.
• W2615103477 cites W2042811466 @default.
• W2615103477 cites W2056052378 @default.
• W2615103477 cites W2060311843 @default.
• W2615103477 cites W2060505458 @default.
• W2615103477 cites W2067283190 @default.
• W2615103477 cites W2076149015 @default.
• W2615103477 cites W2079494033 @default.
• W2615103477 cites W2084030328 @default.
• W2615103477 cites W2097231959 @default.
• W2615103477 cites W2100115202 @default.
• W2615103477 cites W2103793201 @default.
• W2615103477 cites W2111976640 @default.
• W2615103477 cites W2125942853 @default.
• W2615103477 cites W2126236874 @default.
• W2615103477 cites W2128087460 @default.
• W2615103477 cites W2129128353 @default.
• W2615103477 cites W2131109308 @default.
• W2615103477 cites W2131456094 @default.
• W2615103477 cites W2136210739 @default.
• W2615103477 cites W2138732414 @default.
• W2615103477 cites W2142444200 @default.
• W2615103477 cites W2148998801 @default.
• W2615103477 cites W2156923287 @default.
• W2615103477 cites W2158176392 @default.
• W2615103477 cites W2160516412 @default.
• W2615103477 cites W2169285092 @default.
• W2615103477 cites W2419426348 @default.
• W2615103477 cites W2435930479 @default.
• W2615103477 cites W2500075981 @default.
• W2615103477 cites W2528748907 @default.
• W2615103477 cites W2559209228 @default.
• W2615103477 cites W2604800509 @default.
• W2615103477 cites W913623683 @default.
• W2615103477 doi "https://doi.org/10.18632/oncotarget.18025" @default.
• W2615103477 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5589615" @default.
• W2615103477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28903376" @default.
• W2615103477 hasPublicationYear "2017" @default.
• W2615103477 type Work @default.
• W2615103477 sameAs 2615103477 @default.
• W2615103477 citedByCount "22" @default.
• W2615103477 countsByYear W26151034772018 @default.
• W2615103477 countsByYear W26151034772019 @default.
• W2615103477 countsByYear W26151034772020 @default.
• W2615103477 countsByYear W26151034772021 @default.
• W2615103477 countsByYear W26151034772022 @default.
• W2615103477 countsByYear W26151034772023 @default.
• W2615103477 crossrefType "journal-article" @default.
• W2615103477 hasAuthorship W2615103477A5004217317 @default.
• W2615103477 hasAuthorship W2615103477A5016992044 @default.
• W2615103477 hasAuthorship W2615103477A5048840478 @default.
• W2615103477 hasAuthorship W2615103477A5052120847 @default.
• W2615103477 hasAuthorship W2615103477A5053521596 @default.
• W2615103477 hasAuthorship W2615103477A5060787732 @default.
• W2615103477 hasAuthorship W2615103477A5060971333 @default.
• W2615103477 hasAuthorship W2615103477A5077458179 @default.
• W2615103477 hasAuthorship W2615103477A5080643331 @default.
• W2615103477 hasAuthorship W2615103477A5084392897 @default.
• W2615103477 hasBestOaLocation W26151034771 @default.
• W2615103477 hasConcept C121608353 @default.
• W2615103477 hasConcept C126322002 @default.
• W2615103477 hasConcept C143998085 @default.
• W2615103477 hasConcept C2780192828 @default.
• W2615103477 hasConcept C29456083 @default.
• W2615103477 hasConcept C71924100 @default.
• W2615103477 hasConceptScore W2615103477C121608353 @default.
• W2615103477 hasConceptScore W2615103477C126322002 @default.
• W2615103477 hasConceptScore W2615103477C143998085 @default.
• W2615103477 hasConceptScore W2615103477C2780192828 @default.
• W2615103477 hasConceptScore W2615103477C29456083 @default.

• next